Skip to main content Skip to section navigation Skip to footer
Maravai LifeSciences
  • Contact
  • About
    • About Maravai
    • Leadership
    • Board of Directors
    • Innovation
    • Supply Chain
    • Operations
    • Our People
  • Brands
    • Our Brands
    • TriLink BioTechnologies
    • Cygnus Technologies
    • Glen Research
    • Alphazyme
  • Impact
    • Our Impact
    • Maravai Foundation
  • Insights
    • Our Insights
    • Latest news
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • SEC Filings
    • Sustainability
    • Governance
  • Careers
    • Be a #MiracleMaker
    • Current Openings
    • Benefits and Growth
    • Culture and People

Press releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
    • R&D Day 2023
  • Company Info
    • Company Profile
    • Leadership
    • Annual Reports & Proxy
    • Contacts
    • FAQ
    • Analyst Coverage
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Sustainability
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Whistleblower Policy
  • News & Events

  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
  • R&D Day 2023
Apr 13, 2021 4:15 PM EDT

Maravai LifeSciences To Host Earnings Conference Call on Monday, May 10, 2021

Apr 12, 2021 4:30 PM EDT

Maravai LifeSciences Announces Closing of Secondary Offering of Class A Common Stock by Selling Stockholders and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Apr 7, 2021 8:20 PM EDT

Maravai LifeSciences Announces Pricing of an Upsized Secondary Offering of Class A Common Stock by Selling Stockholders

Apr 5, 2021 5:30 PM EDT

Maravai LifeSciences Announces Launch of Proposed Secondary Offering of Class A Common Stock by Selling Stockholders

Apr 5, 2021 4:05 PM EDT

Maravai LifeSciences Announces Preliminary Unaudited First Quarter Revenues and Income From Operations Range

Mar 15, 2021 8:05 AM EDT

Maravai LifeSciences Offers End-to-End mRNA Production with the Launch of TriLink BioTechnologies' Plasmid DNA Manufacturing Services

Mar 2, 2021 4:05 PM EST

Maravai LifeSciences Reports Fourth Quarter and Full Year 2020 Financial Results and Initiates 2021 Financial Guidance

Mar 1, 2021 7:05 AM EST

Maravai LifeSciences Announces March 2021 Investor Conference Schedule

Feb 10, 2021 7:05 AM EST

Maravai LifeSciences Expands Its Intellectual Property Portfolio

Jan 28, 2021 4:15 PM EST

Maravai LifeSciences To Host Earnings Conference Call on Tuesday, March 2, 2021

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
Maravai LifeSciences and its brands are the proven catalysts for helping deliver novel vaccines, therapeutics and diagnostics with biotech, biopharma and life sciences companies across the globe.

Extraordinary science.
Everyday miracles.

  • About
    • Leadership
    • Board of Directors
    • Innovation
    • Supply chain
    • Operations
    • Diversity, equity, and inclusion
  • Brands
    • TriLink BioTechnologies
    • Cygnus Technologies
    • Glen Research
    • Alphazyme
  • Helpful links
    • Investors
    • Insights
    • Be a #MiracleMaker
    • Current openings

Connect with us

  • LinkedIn
  • Terms
  • Privacy notice
  • Site map
© 2025 Maravai LifeSciences. All rights reserved